illumigene® Mycoplasma Direct, illumipro-10
DeviceDNA amplification assay
NCT Number: NCT02511262
The objective of this Clinical Trial is to define the methods to be used to document that illumigene® Mycoplasma Direct meets its intended use claims, using the illumipro instrument, with throat swab samples collected from symptomatic patients.
Looking for future studies?
Notify MeAll sexes
Observational
Sacred Heart Health System, Pensacola, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DNA amplification assay
Time frame: Up to 14 days
Testing of each enrolled subject's samples will be performed within 14 days of collection.
Meridian Bioscience, Inc.
Industry
Clinical Trial Protocol for the Illumigene® Mycoplasma Direct Assay
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00207584
Mycoplasma Pneumoniae
View Trial DetailsNCT06325293
Bacterial Infections, Bacterial Infections and Mycoses
Aarau, Canton of Aargau, Switzerland
View Trial DetailsNCT06640387
Bacterial Infections, Bacterial Infections and Mycoses
Toronto, Ontario, Canada
View Trial Details